Medicenna Therapeutics Corp. MDNAF
0.12 USD 0.00 (-1.60%)
Regular-session close
0.1234 Day range 0.1471
0.123 52-week range 1.19
- YTD
- -81.80%
- 1 year
- -87.38%
News
zacks.com Medicenna Therapeutics (MDNAF) Upgraded to Buy: Here's What You Should Know Medicenna Therapeutics (MDNAF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
globenewswire.com Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update MDNA11 Phase 1/2 ABILITY-1 completes 152-patient enrollment and demonstrates 40% objective response rate (ORR) and 80% disease control rate (DCR) in biomarker-enriched gastrointestinal cancers
